The 3rd Investigator Initiated Trials Summit will be held on November 13-14, 2023 in Philadelphia. The DGE event is focused on exploring the most lucrative ways for reviewing, selecting, and funding research investigators. Researchers, medical officers, health and pharma executives and companies can harness the reach and network of the DGE platform to connect with industry stalwarts and discuss vital issues on how they effectively manage IITs.
The speakers will offer important insights on ways to leverage the new methods for new indications, label expansion and potential publications. The conference aims to create a bridge between pharma suppliers and sponsors who are providing vital data and real-world evidence while remaining…
To know more, please visit https://ibn.fm/AOeXP
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN